Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate
Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…Untargeted Serum Metabolomics Identifies Glycine-Serine Metabolism Disruption as Biochemical Bignature in Parkinson’s Disease
Objective: We attempted to identify a metabolomic signature distinctive of Parkinson’s disease (PD) through an untargeted metabolomics approach. Background: Using an high-performance liquid chromatography targeted…the role of metabotropic glutamate receptors type 3 and 5 in parkinson’s disease: analysis of grm3 and grm5 genbe variants.
Objective: The aim of the study was to examine the association between polymorphic variants of GRM3 and GRM5 and Parkinson’s disease (PD) and motor and…SLC1A7 mutation is a cause of the autosomal dominant form of Parkinson’s disease
Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease
Objective: To generate and characterize induced pluripotent stem cells (iPSCs)-derived in vitro cellular models of Autosomal Recessive Juvenile Parkinsonism (ARJP) carrying Park2 mutations with a…Synaptic Zn2+ Contribution to Parkinson’s Disease Pathophysiology: Pharmacological & Genetic Studies in Preclinical Mouse Models
Objective: The potential involvement of synaptic Zn2+ in development of Parkinson’s disease (PD) motor symptoms and dopaminergic neurodegeneration was investigated. Background: The progressive degeneration of…Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide
Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…mGlu3 receptors in Parkinson’s disease as a candidate target for neuroprotective therapy: evidence from preclinical studies to human genetic.
Objective: In a toxicological model of mouse parkinsonism through chronic injection of MPTP, we examined whether the presence or absence of mGlu3 receptors affected neurodegeneration…The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset
Objective: To determine the effect of positive allosteric modulation of the metabotropic glutamate type 2 (mGlu2) receptor in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset using a low…
- 1
- 2
- 3
- 4
- Next Page »